Table: Anges -Q1 group results
May 9 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2025 Mar 31, 2024 Dec 31, 2025
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 169 mln 113 mln 1.35
(+49.0 pct) (+584.0 pct) (+109.7 pct)
Operating loss 1.26 loss 2.48 loss 5.80
Recurring loss 1.24 loss 1.53 loss 5.82
Net loss 1.25 loss 1.82 loss 5.85
EPS loss 3.99 yen loss 9.14 yen loss 18.68 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001